Vanguard Capital Management
PCVX icon

Vanguard Capital Management’s Vaxcyte PCVX Stock Holding History

Vanguard Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$374M Buy
6,571,828
+223,149
+4% +$13M 0.01% 786
2026
Q2 		$369M Buy
6,348,679
+81,978
+1% +$4.45M 0.01% 820
2026
Q1 		$364M Buy
+6,266,701
New +$340M 0.01% 771

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Capital Management's PCVX Position: Q3 2026 in Review

Vanguard Capital Management increased its Vaxcyte (PCVX) stake by 3.5% in Q3 2026, buying an estimated $13M and bringing the position to 6,571,828 shares worth $374M. The position accounts for 0.01% of the portfolio, ranked #786.

Vanguard Capital Management first reported a position in PCVX in Q1 2026 and has held it in 3 quarters since. 259 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Vanguard Capital Management held 6,571,828 shares of Vaxcyte worth $374M as of Q3 2026.
  • Vanguard Capital Management bought 223,149 Vaxcyte shares in Q3 2026, an estimated $13M.
  • Vaxcyte made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #786 holding.
  • Vanguard Capital Management first reported a position in Vaxcyte in Q1 2026 and has held it in 3 quarters since.
  • 259 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.